Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

BioSyent Inc. (V:RX)

Business Focus: Pharmaceuticals

Log in or join to add this stock to your watch list.
Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEDAR
Company Contact
Address: 170 Attwell Dr Suite 520
ETOBICOKE ON M9W 5Z5
Tel: 1-905-2060013
Website: www.biosyent.com
IR: See website
Key People
Rene C. Goehrum
Chairman of the Board, President, Chief Executive Officer
Robert Joseph March
Chief Financial Officer, Senior Vice President - Finance
Kevin Wilson
Vice President - Sales and Marketing of BioSyent Pharma Inc
Business Overview
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc., acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women's Health Unit, which commercializes pharmaceutical products focused on improving family and women's health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System and Cysview. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. Cathejell is indicated for surface anesthesia and lubrication for various procedures. RepaGyn helps relieve dryness and promotes healing of the vaginal mucosa. It also manufactures and markets Protect-It, a non-toxic product.
Financial Overview
For the three months ended 31 March 2019, Biosyent Inc. revenues increased 1% to C$4.5M. Net income decreased 14% to C$978K. Revenues reflect Canada segment increase of 15% to C$4.5M. Net income was offset by Advertising, promotion and sales people increase of 15% to C$638K (expense), Employee cost increase of 14% to C$644K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from C$0.08 to C$0.07.
Reporting Currency: Canadian Dollars
Enterprise value: $75.36M as of Mar 31, 2019
Annual revenue (TTM): $21.56M as of Mar 31, 2019
EBITDA (TTM): $6.95M as of Mar 31, 2019
Net annual income (TTM): $5.54M as of Mar 31, 2019
Free cash flow (TTM): $5.55M as of Mar 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 13,834,915 as of Jun 27, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization